Atlas Trials

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

Clinical trial NCT05492578 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT05492578
Sponsor
Sanofi
Status
ENROLLING_BY_INVITATION
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Dermatitis Atopic
Start date
2022-08-22
Primary completion
2029-01-22
Enrollment
1663

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.